APA (7th ed.) Citation

Ciardiello, F., Yoshino, T., Modest, D., Martin Fernandez, L., Roby, L., Fougeray, R., . . . Tabernero, J. (2022). 436TiP COLSTAR: Randomized, open-label, multicentre, phase III study comparing futuximab/modotuximab plus trifluridine/tipiracil to trifluridine/tipiracil in KRAS/NRAS and BRAF wild type (wt) metastatic colorectal cancer (mCRC) previously treated with both standard and anti-EGFR treatment. Annals of Oncology, 33, S733. https://doi.org/10.1016/j.annonc.2022.07.574

Chicago Style (17th ed.) Citation

Ciardiello, F., T. Yoshino, D.P Modest, L. Martin Fernandez, L. Roby, R. Fougeray, B.P Lockhart, and J. Tabernero. "436TiP COLSTAR: Randomized, Open-label, Multicentre, Phase III Study Comparing Futuximab/modotuximab Plus Trifluridine/tipiracil to Trifluridine/tipiracil in KRAS/NRAS and BRAF Wild Type (wt) Metastatic Colorectal Cancer (mCRC) Previously Treated with Both Standard and Anti-EGFR Treatment." Annals of Oncology 33 (2022): S733. https://doi.org/10.1016/j.annonc.2022.07.574.

MLA (9th ed.) Citation

Ciardiello, F., et al. "436TiP COLSTAR: Randomized, Open-label, Multicentre, Phase III Study Comparing Futuximab/modotuximab Plus Trifluridine/tipiracil to Trifluridine/tipiracil in KRAS/NRAS and BRAF Wild Type (wt) Metastatic Colorectal Cancer (mCRC) Previously Treated with Both Standard and Anti-EGFR Treatment." Annals of Oncology, vol. 33, 2022, p. S733, https://doi.org/10.1016/j.annonc.2022.07.574.